A Phase 1, Non-Randomized, Open-Label Trial to Evaluate the Effect of Hepatic Impairment on the Single Dose Pharmacokinetics of Intravenous TAK-954
Phase of Trial: Phase I
Latest Information Update: 22 Jan 2018
At a glance
- Drugs TD 8954 (Primary)
- Indications Gastrointestinal motility disorders
- Focus Pharmacokinetics
- Sponsors Takeda
- 12 Jan 2018 Status changed from not yet recruiting to recruiting.
- 18 Oct 2017 Planned End Date changed from 2 Jun 2018 to 28 Jun 2018.
- 18 Oct 2017 Planned primary completion date changed from 2 Jun 2018 to 28 Jun 2018.